At e-SPACE CRM 2022 clinical data was analysed through a practical lens to address questions around SGLT2 inhibitor use in CKD.
Explore the data-supported discussion of the treatment landscape for patients with CKD, and other comorbidities. The inciteful conversation is led by Dr Muthiah Vaduganathan (Chair) and Professor Mustafa Arici.
This educational symposium will increase delegates' understanding of:
- SGLT2 inhibitors as part of the evidence-based CKD treatment landscape
- Data supporting the cardiorenal efficacy of SGLT2 inhibition in comorbid patients with CKD
- How clinical data from SGLT2 inhibitor trials should be applied in clinical practice
Target Audience
- Cardiologists
- Nephrologists
More from this programme
Faculty Biographies
Muthiah Vaduganathan
Co-Director, Center for Cardiometabolic Implementation Science
Dr Muthiah Vaduganathan is a Cardiologist and Clinical Trialist at Brigham and Women’s Hospital and Harvard Medical School, Boston, US. He is co-director of the Center for Cardiometabolic Implementation Science at Brigham and Women’s Hospital. He serves as an Associate Editor of JACC and as US national ambassador to the ESC Heart Failure Association. His research focuses on drug development, clinical trials, and implementation of cardio-kidney-metabolic therapies, and he has authored or co-authored more than 700 peer-reviewed publications. He participates on study leadership of ongoing advanced-phase trials in cardio-kidney-metabolism and heart failure.